Insights from a new paper outline the unique considerations and management approaches for patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation.

Currently approved treatment options for Group 1 PAH, although effective, are not curative options for patients.

In patients with end-stage disease, lung transplantation has been posited as an option to improve survival and health-related quality of life.

PAH is the only major diagnostic indication for transplantation that is not a parenchymal pulmonary process.

Read More